AI is changing
your health
Here's what it means for you.
Every week, the biggest AI breakthroughs in medicine — explained in plain English. What's real, what's hype, and what it could mean for your health. No medical degree required.
Post-adjuvant chemotherapy in ctDNA-positive patients with resected colorectal cancer: a randomized phase 3 trial
Using chemotherapy to treat colorectal cancer patients who test positive for tumor DNA during recovery does not significantly delay cancer recurrence compared to a placebo.
Why people read Mednosis
We turn the firehose of medical-AI research into clear, trustworthy stories anyone can follow — clinicians included.
In plain English
Every breakthrough explained without the jargon — what it is, what they found, and why it could matter for your health.
No hype, just facts
We fact-check every summary against the original source and rate how close each finding really is to everyday care.
Depth on demand
Want the science? One tap reveals the clinical detail — study design, sample sizes, and limitations. Clinicians, this is for you.
Latest Research
Effects of SGLT2 inhibition on incident heart failure in carriers of cardiomyopathy-associated genetic variants
Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial
Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial
Four Scenarios of AI Scribe Adoption in Healthcare
Rehumanizing global health care with agentic AI
Get smarter about medical AI every week
Join clinicians and researchers staying ahead of the curve
Trending This Week
Research getting the most attention
Effects of SGLT2 inhibition on incident heart failure in carriers of cardiomyopathy-associated genetic variants
Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial
Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial
Find What Matters to You
Filter research by how close it is to clinical practice
Browse by Specialty
Find research relevant to your field
Never Miss a
Breakthrough
Get curated AI in medicine research delivered weekly. No spam, unsubscribe anytime.
AI in Medicine 101
Learn how to read medical AI research, spot red flags in hype-y articles, and ask the right questions about new technologies.